Report of Foreign Issuer (6-k)
November 01 2019 - 1:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
The
exercise of options over 137,040 Ordinary Shares, granted on 22
July 2010 under the GlaxoSmithKline 2009 Share Option
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.035
|
137,040
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-10-31
|
|
f)
|
Place of the
transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
The
sale of 112,945 Ordinary Shares to cover the tax and cost of
exercise of the options granted on 22 July 2010 under the
GlaxoSmithKline 2009 Share Option Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.7588
|
112,945
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-10-31
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Transfer of 24,095 Ordinary Shares to spouse for nil
consideration.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
24,095
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated volume
Price
|
|
|
e)
|
Date
of the transaction
|
2019-10-31
|
|
f)
|
Place of the
transaction
|
N/A
|
|
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr David Owen
|
|
b)
|
Position/status
|
PCA of Ms E Walmsley (Chief Executive Officer)
|
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Receipt of 24,095 Ordinary Shares from spouse for nil
consideration.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£0.00
|
24,095
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated volume
Price
|
|
|
e)
|
Date
of the transaction
|
2019-10-31
|
|
f)
|
Place of the
transaction
|
N/A
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
01, 2019
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
